Copycat Weight-Loss Drugs Are Major Players With Consumers ...Middle East

As many as 1 in 8 American adults has tried one of the GLP-1 anti-obesity drugs, but a surprising number aren’t getting their supplies from pharma giants Novo Nordisk or Eli Lilly. Up to 30 percent of the market, by some estimates, is made up of copycat versions from compounding pharmacies. Compounding is legal, though the resulting products sometimes fall into a gray area because they’re copies of drugs under patent and are not approved by the Food and Drug Administration. Mark Mikhael, CEO of Orlando-based Olympia Pharmaceuticals, estimates that his and other large compounders provision up to 2 million Americans each month with semaglutide, the scientific name for Novo Nor

Hence then, the article about copycat weight loss drugs are major players with consumers was published today ( Wednesday 31/07/2024 - 04:45 PM ) and is available on KHN ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Copycat Weight-Loss Drugs Are Major Players With Consumers )

Also on site :

• The Supreme Court Cast Its Lot With Trumpism. It Should Be Very Worried.
• UN renews Sudan ceasefire appeal over ‘unimaginable suffering’ of civilians
• Israeli forces continue ceasefire violations with attacks across Gaza